First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1) - Concepedia

Concepedia

Publication | Open Access

First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)

DOI Full Paper Access

59

Citations

28

References

2023

Year

Sophie Postel‐Vinay, Vincent K. Lam, Willeke Ros, Todd M. Bauer, Aaron R. Hansen, Daniel C Cho, F. Stephen Hodi, Jan H.M. Schellens, Jennifer K. Litton, Sandrine Aspeslagh,

Journal for ImmunoTherapy of Cancer

Abstract

NCT02528357.

References

	Year	Citations

Page 1